Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Reporting Date: December 16, 2024 (Earliest event reported)
Significant Dates: December 16, 2024 and December 20, 2024
Context: The Company entered into two separate securities purchase agreements to issue convertible promissory notes to investors. Proceeds are designated for general working capital purposes.
Key Financial Metrics
This filing details debt financing activities rather than operational performance metrics. Revenue, profit, cash flow, and margins are not reported in this document.
| Note Date | Principal Amount | Purchase Price | Interest Rate/Charge | Maturity Date |
|---|---|---|---|---|
| December 16, 2024 | $22,000 | $20,000 | 8% per annum | June 15, 2025 |
| December 20, 2024 | $49,200 | $41,000 | 15% one-time charge ($7,380) | October 15, 2025 |
Total Principal Raised: $71,200
Total Cash Proceeds: $61,000
Material Changes and Terms
The Company has incurred new direct financial obligations through the issuance of two convertible notes with distinct terms:
- Note 1 (Dec 16):
- Conversion: Convertible at $0.0003/share after 6 months. If stock trades below $0.0003 for 5+ days, price adjusts to $0.0001. In default, price is the lowest trading price.
- Prepayment: Allowed with penalties ranging from 110% to 125% of face value depending on timing (within 180 days). No prepayment right after 180 days.
- Reserves: Company must maintain a reserve of 500% of the number of conversion shares.
- Note 2 (Dec 20):
- Repayment: Principal and interest ($56,580 total) payable in five installments starting June 15, 2025.
- Conversion: Only upon Event of Default. Conversion price is 65% of the lowest trading price over the prior 10 days (35% discount).
- Prepayment: Allowed at any time with no penalty.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to use net proceeds for general working capital. No specific operational guidance or outlook was provided in this filing.
Risks and Contingencies:
- Events of Default: Both notes include standard defaults (non-payment, insolvency, bankruptcy) and specific covenants regarding SEC reporting compliance and maintaining OTC market listing.
- Dilution Risk: Significant dilution potential exists if conversion prices adjust downward due to low stock prices or default events.
- Liquidity Pressure: The first note restricts prepayment after 180 days, while the second note requires immediate installment payments starting June 2025.
Investor Verification Checklist
- Verify the Company's current cash position to assess ability to meet the first installment payment of $28,290 due June 15, 2025.
- Confirm the Company's compliance status with SEC reporting requirements to avoid triggering default clauses.
- Review the Company's authorized share count to ensure the 500% reserve requirement for the first note can be met.
- Monitor the trading price of Common Stock on OTC Markets, as prices below $0.0003 could trigger a significant reduction in the conversion price for the first note.
- Examine the full text of Exhibits 10.1, 10.2, 4.1, and 4.2 for additional covenants not summarized here.